Albany, NY -- (SBWIRE) -- 01/16/2018 -- According to a research report recently published by Transparency Market Research, revenues of about US$3.8 bn are expected to be generated through six drugs aimed at treating hospital acquired pneumonia by 2020. The leading market intelligence provider has released a research report on the global pipeline hospital acquired pneumonia drugs market. "Pipeline Analysis of Hospital Acquired Pneumonia Drugs Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020" will provide its users with a crystal clear vision of the drugs currently under testing and development and how they will shape the future of this market.

Unlike generally acquired infections and pneumonia, hospital acquired infections are highly resistant to conventional drugs. This creates major problems for patients who are already under treatment for other ailments. Hospital acquired pneumonia usually shows immunity to multiple drugs. It usually becomes a case of comorbidity, drastically reducing a weaker patient's chances of recovering.

According to the report, there are six drugs currently in the final phases (phase III) of the global hospital acquired pneumonia market pipeline. Of these, five are investigational drugs while another is a vaccine. These are considered to be the leading answers to curbing the high prevalence of hospital acquired pneumonia. Moreover, there are ten other drugs in the early stages of the global hospital acquired pneumonia market pipeline.

As stated in the report, the six phase III drugs in the global hospital acquired pneumonia market pipeline are Tedizolid phosphate by Cubist Pharmaceuticals, Amikacin inhale by Bayer Healthcare, Ceftolozane/tazobactam, Synflorix by GSK, Plazomicin by Achaogen, Inc., and Ceftazidime/avibactam by AstraZeneca PLC.

With a maintenance of schedules, these six drugs are expected to be available in 2017, if they are approved.

One of the major trends visible in the global hospital acquired pneumonia market is the shift in preference from conventional antibiotic drugs to the modern, novel biological drugs. This can be noticed in the fact that most of the final stage drugs in the global hospital acquired pneumonia market pipeline are biological drugs.

The report also takes up citations from the U.S. CDC, according to which at least 63% of the variants of acinetobacter are resistant to multiple drugs. Meanwhile, the most prominent MRSA was the most dangerous and prominent organism associated with hospital acquired pneumonia. The CDC had also revealed that nearly 11,000 of the 80,400 patients who contracted MRSA-based HAIs had died.

The WHO adds to this with a study that revealed low income and medium income families to be the most susceptible to HAIs. These factors need to be considered by the global hospital acquired pneumonia market in the development of new drugs.

Request for Sample Copy of Report @ https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=1881

The key players in the global hospital acquired pneumonia market pipeline for now, include the companies named above. For the overall global hospital acquired pneumonia market, the report takes into consideration the player profiles of Basilea Pharmaceutica Ltd., Meiji Seika Pharma Co. Ltd., Cubist Pharmaceutical, Valneva SE., Aridis Pharmaceutical, Bayer Healthcare, GlaxoSmithKline, Merck & Co., Achaogen, Inc., and AstraZeneca PLC.